Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. reports financial results and operating updates for a consumer wellness business focused on hemp extracts, CBD products and natural wellness ingredients. News commonly covers revenue trends, gross margin, operating expense reductions, adjusted EBITDA, cash flow objectives and balance-sheet actions such as secured note amendments and convertible debt features.
Company updates also include product launches across +PlusCBD, +PlusHLTH, Ignite and Empowr, including CBD gummies, pet products, cannabinoid-free supplements and plant-based nutrition formulas. Recurring coverage also addresses the evolving regulatory environment for hemp-derived CBD and the company’s efforts to broaden its wellness product portfolio.
CV Sciences (OTCQB:CVSI) reported Q1 2026 revenue of $3.2 million, down 11.4% year over year, with units sold down 12.2%. Gross margin was 48.9%. Operating loss was $0.3 million and adjusted EBITDA loss $0.1 million. Operating expenses fell 13.3% to $1.9 million, cash ended at $0.3 million. The company completed a debt restructuring, launched its EMPOWR wellness product, and noted that 43% of Q1 2026 net revenue came from 45 products launched since January 1, 2023.
CV Sciences (OTCQB:CVSI) will release first quarter 2026 financial results for the period ended March 31, 2026, after the market close on Thursday, May 14, 2026.
The company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET), with a live webcast and 30-day archive.
CV Sciences (OTCQB:CVSI) reported fiscal 2025 revenue of $13.8M, down 12.2% from 2024, with year-end cash of $0.3M. Gross margin improved to 49.0% from 45.6%, operating expenses fell 17.2% to $7.7M, and adjusted EBITDA narrowed to a $0.3M loss, with positive adjusted EBITDA of $0.1M in Q4. The company completed a debt restructuring (Q1 2026) and launched new products including Ignite (Q3 2025) and EMPOWR (Q1 2026).
Management emphasized margin expansion, cost cuts, and targeted M&A to pursue sustainable profitability and cash flow in 2026.
CV Sciences (OTCQB:CVSI) will release year‑end and fourth quarter 2025 results after market close on March 26, 2026 and will host a conference call the same day at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and archived replay will be available via the company's Investor Relations site.
Telephone participation and a replay are provided, with the replay available through April 2, 2026 using confirmation code 13759006.
CV Sciences (OTCQB:CVSI) announced a debt restructuring that adds a conversion feature allowing outstanding notes to be converted into common shares at a fixed price of $0.06 per share. The company says this change aims to strengthen the balance sheet and increase financial flexibility to support growth and product expansion, including the new Empowr plant-based protein and creatine formula under the +PlusHLTH™ line.
CV Sciences (OTCQB:CVSI) launched Empowr on February 26, 2026, a dairy-free, plant-based protein and creatine powder designed for everyday wellness. Empowr delivers 20g protein, 5g creatine, and LactoSpore® probiotics per serving to support strength, mental energy, and digestive balance.
The product combines pea, hemp, and sunflower protein with creatine and Bacillus coagulans probiotics, expanding CV Sciences' wellness portfolio alongside its +PlusHLTH line.
CV Sciences (OTCQB:CVSI) said it is positioned to participate in a newly announced Medicare and Medicaid Pilot Program for CBD following an Executive Order directing HHS agencies to expand cannabidiol research and regulated access. The company highlighted its decade-long clinical research track record and its self-affirmed GRAS status for hemp extract products as bases for participation. The announcement notes CMS plans for a pilot to allow senior patients reimbursement for CBD, with a goal to begin on April 1, 2026.
CV Sciences (OTCQB:CVSI) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $3.3M, down from $3.9M in Q3 2024 and down from $3.6M in Q2 2025. Gross margin improved to 48.5% versus 46.0% a year earlier. Adjusted EBITDA was a loss of $118k versus a $75k loss in Q3 2024. Cash at quarter end was $0.4M. Units sold declined by 16% year-over-year. Management highlighted new product expansion, including the launch of Ignite, and cited restrictive federal hemp language with a one-year delayed effect.
The company will host a conference call and webcast today at 4:30pm EDT/1:30pm PDT.
CV Sciences (OTCQB: CVSI) will release its third quarter 2025 financial results after market close on Thursday, November 13, 2025.
The company will host a conference call with investors at 1:30 p.m. PT / 4:30 p.m. ET on the same day. A live webcast will be available on the investor relations site at https://ir.cvsciences.com/news-events and directly at the provided webcast link. The webcast will be archived for approximately 30 days.
Live call participants may dial (877) 407-0784 (U.S.) or (201) 689-8560 (international); callers are asked to dial 15 minutes early. A telephone replay will be available about two hours after the call until Thursday, November 20, 2025 via replay numbers and confirmation code 13756671.
CV Sciences (OTCQB:CVSI) has launched Ignite, a new men's performance formula combining clinically-supported botanicals with full spectrum CBD. The product targets men aged 35+ seeking natural support for vitality, recovery, and focus.
The formula features key botanicals including Tongkat Ali for testosterone and energy support, Panax Ginseng for stamina and focus, and Tribulus Terrestris for libido enhancement. This launch adds to CV Sciences' expanding product portfolio, which includes +PlusHLTH™, +PlusCBD™ Extra Support Sleep and Calm Gummies, Reserve gummies, and pet products.